Aardvark Therapeutics, Inc. Common Stock
AARDNASDAQHealthcare● Active
$3.59
$-0.09(-2.45%)
Market Cap$78320822
P/E Ratio—
52W High$17.94
52W Low$3.35
Aardvark Therapeutics, Inc. Common Stock (AARD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AARD · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.99
Est. -$0.87 · -14.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
AARD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.86 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.87 | -$0.99 | -14.0% | — | — | — |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$0.83 | -$0.81 | +2.1% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.80 | -$0.75 | +6.1% | — | — | — |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$0.60 | -$0.66 | -10.0% | — | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.67 | -$0.71 | -5.5% | — | — | — |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$0.41 | -$0.68 | -65.9% | — | — | — |
| — Q3 FY2024 | Sep 30, 2024 | — | -$0.32 | — | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.86
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.99
EPS Est.
-$0.87
EPS Surpr.
-14.0%
Revenue
—
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
-$0.81
EPS Est.
-$0.83
EPS Surpr.
+2.1%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.75
EPS Est.
-$0.80
EPS Surpr.
+6.1%
Revenue
—
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$0.66
EPS Est.
-$0.60
EPS Surpr.
-10.0%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.71
EPS Est.
-$0.67
EPS Surpr.
-5.5%
Revenue
—
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$0.68
EPS Est.
-$0.41
EPS Surpr.
-65.9%
Revenue
—
Q3 FY2024
Sep 30, 2024
EPS Actual
-$0.32
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-2.05 | $-2.05 | $-2.05 | 5 |
| Q3 FY2028 | $-1.65 | $-1.65 | $-1.65 | 5 |
| Q2 FY2028 | $-1.20 | $-1.20 | $-1.20 | 6 |
| Q1 FY2028 | $-0.97 | $-0.97 | $-0.97 | 3 |
| Q4 FY2027 | $-0.88 | $-0.88 | $-0.88 | 2 |
| Q3 FY2027 | $-0.88 | $-0.88 | $-0.88 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -14.0% | $5.89 | $5.60 | -4.92% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +2.1% | $4.07 | $4.07 | +0.00% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +6.1% | $10.73 | $10.86 | +1.21% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -10.0% | $10.04 | $11.20 | +11.55% |
| ▼ Q2 FY2025 | May 14, 2025 | -5.5% | $10.14 | $8.74 | -13.81% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -65.9% | $13.65 | $13.11 | -3.96% |
| — Q3 FY2024 | Sep 30, 2024 | — | No price data | $14.31 | — |
| — Q2 FY2024 | Jun 30, 2024 | — | No price data | $14.31 | — |
Q2 FY2026-4.92%
Report Date
May 7, 2026
EPS Beat/Miss
-14.0%
Price Before
$5.89
Price After
$5.60
Q1 FY2026+0.00%
Report Date
Mar 23, 2026
EPS Beat/Miss
+2.1%
Price Before
$4.07
Price After
$4.07
Q4 FY2025+1.21%
Report Date
Nov 13, 2025
EPS Beat/Miss
+6.1%
Price Before
$10.73
Price After
$10.86
Q3 FY2025+11.55%
Report Date
Aug 13, 2025
EPS Beat/Miss
-10.0%
Price Before
$10.04
Price After
$11.20
Q2 FY2025-13.81%
Report Date
May 14, 2025
EPS Beat/Miss
-5.5%
Price Before
$10.14
Price After
$8.74
Q1 FY2025-3.96%
Report Date
Feb 26, 2025
EPS Beat/Miss
-65.9%
Price Before
$13.65
Price After
$13.11
Q3 FY2024—
Report Date
Sep 30, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$14.31
Q2 FY2024—
Report Date
Jun 30, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$14.31
Avg Beat Reaction+0.60%
Avg Miss Reaction-2.79%
Beat Rate2 / 8 quarters
Largest Move-13.81% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AARD ends December
Aardvark Therapeutics, Inc. Common Stock (AARD) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.99 — missing the analyst consensus of $-0.87 by -14.0%. The next AARD earnings date is expected around September 1, 2026.
Each quarter, investors track AARD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AARD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AARD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AARD earnings · 5 questionsAardvark Therapeutics, Inc. Common Stock's next earnings report is expected around September 1, 2026. AARD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AARD historically reports after market close (AMC).
AARD earnings datewhen is AARD earningsAARD next earnings datewhen does AARD report earningsAARD earnings calendar
▸ Source: FMP · Aardvark Therapeutics, Inc. Common Stock SEC filings · US GAAP · Aardvark Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026